Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 20.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 898,895 shares of the company’s stock after selling 227,690 shares during the period. Epoch Investment Partners Inc.’s holdings in Amphastar Pharmaceuticals were worth $17,609,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth $2,504,000. Denali Advisors LLC grew its holdings in shares of Amphastar Pharmaceuticals by 56.9% in the fourth quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock valued at $5,671,000 after purchasing an additional 76,765 shares during the period. Bridge City Capital LLC grew its holdings in shares of Amphastar Pharmaceuticals by 72.8% in the fourth quarter. Bridge City Capital LLC now owns 235,485 shares of the company’s stock valued at $6,306,000 after purchasing an additional 99,227 shares during the period. TD Asset Management Inc grew its holdings in shares of Amphastar Pharmaceuticals by 1.6% in the fourth quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock valued at $52,571,000 after purchasing an additional 31,160 shares during the period. Finally, Cibc World Market Inc. acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $1,666,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ:AMPH opened at $18.72 on Friday. The company has a market capitalization of $825.36 million, a price-to-earnings ratio of 11.28, a PEG ratio of 3.68 and a beta of 0.89. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $31.26. The business has a 50-day moving average price of $19.32 and a 200 day moving average price of $21.91. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million during the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. Sell-side analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.41 EPS for the current year.

Analyst Upgrades and Downgrades

AMPH has been the topic of a number of analyst reports. Barclays reduced their target price on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Bank of America reaffirmed an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Six analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $22.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.